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Abstract
Background: Delirium is a very common and distressing neuropsychiatric syndrome in palliative care. Increasing
age, the presence of dementia and advanced cancer are well-known predisposing risk factors for delirium
development. Sleep-wake cycle disturbance is frequently seen during delirium and melatonin has a pivotal role in
the regulation of circadian rhythms. Current evidence across various settings suggests a potential preventative role
for melatonin in patients at risk of delirium, but no studies are currently reported in patients with advanced cancer.
The aim of this article is to describe the design of a feasibility study that is being conducted to inform a larger
randomized, placebo-controlled, double-blind trial (RCT) to evaluate the role of exogenously administered
melatonin in preventing delirium in patients with advanced cancer.
Methods/Design: Adult patients with a cancer diagnosis who are admitted to the palliative care unit will be
randomized into a treatment or placebo group. The pharmacological intervention consists of a single daily dose of
immediate-release melatonin (3 mg) at 21:00 ± 1 h, from day 1 to day 28 of admission. The primary objective of this
initial study is to assess the feasibility of conducting the proposed RCT by testing recruitment and retention rates,
appropriateness of study outcome measures, acceptability of study procedures and effectiveness of the blinding
process. The primary outcome measure of the proposed larger RCT is time to first inpatient incident episode of
delirium. We also plan to collect data on incident rates of delirium and patient-days of delirium, adjusting for
length of admission.
Discussion: The outcomes of this feasibility study will provide information on recruitment and retention rates,
protocol violation frequency, effectiveness of the blinding process, acceptability of the study procedures, and safety
of the proposed intervention. This will inform the design of a fully powered randomized controlled trial to evaluate
the preventative role of melatonin administration in patients with advanced cancer.
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Background
Delirium is a very common and distressing neuropsychi-
atric syndrome for patients and their families in palliative
care settings [1–3]. Delirium occurrence rates of over 80 %
have been reported in the last hours and days before death
[4, 5]. Conducting research in this population is challen-
ging and, not surprisingly literature, data are limited owing
to patient frailty and high attrition rates in association with
the context of advanced disease [6–8].
Delirium is characterized by altered awareness, atten-
tion and cognitive deficits, perceptual disturbances, and
a fluctuating course with potential intervals of relative
lucidity that likely contribute to its underdiagnosis [9].
Delirium impairs patient communication, thus challenging
the assessment of pain and other symptoms [1]. It often
occurs at a critical juncture in advanced disease, when a
preexisting narrow window of opportunity to communi-
cate with family may be further compromised.
Delirium is associated with increases in morbidity,
mortality, health care costs and, most importantly, in
levels of patient and family distress [10–17]. Increasing
age and the presence of dementia are well-known predis-
posing risk factors for the development of delirium [18].
Given the increasing elderly proportion of the population,
and that cancer is predominantly a disease of the elderly,
there is a fundamental need to develop primary, secondary
and tertiary preventative strategies for delirium in these
patients [19, 20]. Using early prophylactic strategies
may reduce incident delirium, thereby reducing patient
morbidity and mortality, [21] and suffering [22].
Although a multicomponent intervention study in a
geriatric setting resulted in a 34 % reduction in delirium
incidence, [23] a less elaborate intervention strategy that
targeted cancer patients in palliative care settings failed
to demonstrate a reduction in delirium incidence, though
many study limitations were noted [22]. The recently
published National Institute for Health and Clinical
Excellence (NICE) guideline on the diagnosis, prevention
and management of delirium concluded that delirium
prevention would be cost-effective and that approxi-
mately 30 % of all episodes of delirium could be pre-
vented through a multicomponent package of basic care
interventions, many of a nonpharmacological nature [18].
A recent Cochrane review affirmed the urgent need for
well-designed trials of delirium prevention [24, 25]. In
2010, the Canadian Coalition for Seniors’ Mental Health
published “Guidelines on the assessment and treatment
of delirium in older adults at the end of life” [26]. Prior
to conducting a larger preventative trial, we plan to imple-
ment these guidelines on our palliative care unit in tandem
with a feasibility study to examine the role of melatonin in
the prevention of delirium.
Although the phenomenon of sleep-wake cycle dis-
turbance is not a core diagnostic criterion for delirium,
its prevalence has been reported in the 75–100 % range
in studies of delirium in cancer patients [27, 28]. This
phenomenon most likely reflects a circadian rhythm dis-
turbance [29–31]. Melatonin (N-acetyl-5-methoxytrypta-
mine) is a neuro-hormone that is derived sequentially
from tryptophan and serotonin. Two enzymes in the
pineal gland subsequently catalyze the synthesis of mela-
tonin from serotonin [32]. Melatonin has a pivotal role
in the regulation and synchronization of the sleep-wake
cycle and circadian rhythms. Melatonin has immune-
enhancing, anti-inflammatory and anticachectic effects,
in addition to antioxidant and oncostatic properties
[33–36]. It is secreted in response to retinal photorecep-
tors releasing norepinephrine with the onset of darkness.
Endogenous plasma melatonin levels begin to rise around
22:00 h at night, peak around 03:00 h at approximately
100 pg/ml, before dropping back to usual low daytime
levels by 09:00 h [37]. Endogenous peak plasma melatonin
levels vary greatly between individuals and are reduced
with age, increased cognitive impairment and in critical
illness [37–39]. Melatonin is rapidly metabolized, mainly
in the liver, by hydroxylation. Following subsequent conju-
gation with sulphuric or glucuronic acid, it is excreted in
the urine [32, 40]. The chief metabolite of melatonin, 6-
sulfatoxymelatonin (6-SMT), closely parallels serum mela-
tonin concentrations in healthy individuals [32, 37, 40].
The role of melatonin in the pathogenesis of delirium has
been hypothesized in terms of a deficient state and sleep
dysregulation [41–43].
Melatonin supplementation has been suggested as a
preventative measure for patients at risk of postoperative
delirium [44, 45]. Further interest in this role of prophy-
lactic exogenous melatonin treatment has been prompted
by a 2010 systematic review, which concluded that in
addition to melatonin having benefit in the reduction of
“sundowning” or agitated behavior in dementia patients, it
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could have the same positive effects in patients with
delirium [29]. More recently, a randomized, placebo-
controlled, double-blind trial in 145 elderly internal
medicine inpatients in London, Ontario reported a reduced
risk of delirium in the low-dose (0.5 mg) melatonin-treated
group versus placebo, reflected by incidence rates of 12 %
versus 31 %, respectively [46]. A subgroup analysis in
a recent meta-analysis concluded that melatonin sup-
plementation reduced the incidence of delirium by 75 %
in hospitalized medical patients of 65 years of age or older
[47]. Melatonin appears to be well-tolerated and few
serious side effects have been reported [48–50]. We
hypothesize that melatonin may have a preventative
role in the management of delirium in the palliative
care population. Given the absence of data on its use
in this population and the mixed results in other pop-
ulations, we plan to test our hypothesis in a randomized
controlled trial (RCT). The primary outcome measure of
the proposed RCT is time to first inpatient incident epi-
sode of delirium. We also plan to collect data on incident
rates of delirium and patient-days of delirium, adjusting
for length of admission.
The challenges of conducting RCTs in palliative care
settings have been well-documented [51]. Hagen et al.
make a strong case for conducting an initial formal feasi-
bility study prior to a RCT: this allows researchers to test
the multiple dimensions of feasibility such as recruit-
ment, retention and acceptability of study procedures
[51]. This paper describes the design of a pilot and feasi-
bility study to examine the preventative role of exogen-
ous melatonin administration in patients with advanced
cancer who are at risk of delirium. We chose to use an
immediate-release (IR) preparation of melatonin as this
formulation may have the advantage of providing a
short-lived higher peak concentration of melatonin when
compared to slow-release preparations [52]. In addition,
an IR preparation would appear to better replicate the nat-
ural circadian pattern of in-vivo melatonin secretion and
thus facilitate its potential regulatory role in homeostasis.
There is at least some degree of semantic ambiguity in
the literature regarding the distinction between feasibility
and pilot studies [53]. Given that our feasibility study will
represent a miniature version of the larger randomized
trial, we therefore also view this feasibility study as a pilot
study. For consistency of reference, we will mainly use the
term feasibility study in this publication.
Primary objective of the feasibility study
To assess the feasibility of conducting a proposed RCT
by determining (1) recruitment rates and retention rates,
(2) the appropriateness of the main study outcome mea-
sures as indicated by protocol violation frequency, and
some preliminary data on time to onset of first episode
of incident delirium during their inpatient admission, (3)
the acceptability of the study procedures to patients,
families and palliative care unit staff including pharmacy,
and (4) the effectiveness of the blinding process.
Secondary objectives of the feasibility study
1. To make necessary adjustments to the main study
protocol and assess subsequent feasibility in an
iterative manner. This includes a feasibility
assessment of the data collection process in relation
to the predisposing and precipitating risk factors for
delirium
2. To facilitate the concomitant implementation of
standard delirium prevention and management
guidelines on the palliative care unit prior to
proceeding with the main RCT
3. To assess the safety of the proposed intervention in
this population
Methods/Design
Study setting
This study is being conducted on the 31-bed inpatient
palliative care unit (PCU) at Élisabeth Bruyère Hospital,
a university teaching unit at Bruyère Continuing Care in
Ottawa, Ontario, Canada. The study is sponsored by
Bruyère Research Institute.
Study design
This investigator-initiated feasibility study is a random-
ized, placebo-controlled, double-blind, single-center trial
of a daily administered single dose of melatonin adminis-
tered per os to prevent delirium in patients with advanced
cancer. It is being conducted in order to inform a larger
randomized, placebo-controlled, double-blind, parallel-
group, multicenter trial. Figure 1 shows the Consolidated
Standards of Reporting Trials (CONSORT) overview of
the larger RCT that will be piloted in our feasibility study.
A populated Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) checklist for this manu-
script is also provided (see Additional file 1).
Sample size
There are varying viewpoints regarding the appropriate
sample size for feasibility and pilot studies [54]. Whereas
estimation may be guided on the basis of confidence in-
tervals and standard deviation for continuous outcome
measures, the situation is less clear in the case of pilot
studies with time to event measures, such as time to onset
of first incident episode of delirium. In inpatient palliative
care settings, delirium incidence rates have been reported
in the 3–45 % range [55]. In our main RCT, we anticipate
a delirium incidence rate of approximately 25 % in the
placebo arm by day 28 of admission. This would result in
a 75 % administrative censoring proportion in the larger
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study. In addition, we arbitrarily set the anticipated
proportion of noninformative censoring due to withdrawal
or loss to follow-up at 10 %. We currently estimate a
sample size requirement of N = 410 for the main study to
detect an effect size (hazard ratio) of 0.5, given an alpha
level of 0.05 and power of 80 %, using STATA version 14.1
(StataCorp LP, College Station, TX, USA) [56]. We further
estimate that a sample size of 60 (arbitrarily set at approxi-
mately 15 % of the currently projected sample size of the
larger study) with 30 participants in each arm will be
adequate to provide useful data regarding the feasibility
outcome measures.
Recruitment and consent
Potential participants will be approached within 72 h of
admission to the PCU. An assessment will be made by
the attending physician as to their capacity to under-
stand the risks and benefits of participation in a trial. A
member of the primary “circle of care” will ask potential
participants or their substitute decision-maker (SDM)
for their verbal consent to be contacted by an authorized
research team member. Following this initial consent,
potential participants or their SDM will be approached by
a clinical research nurse (CRN) or a clinical research as-
sistant (CRA) and be provided with written and oral
information about the study, including risks and benefits.
If a participant or their SDM chooses to enroll, signed in-
formed consent is obtained before commencing the study.
Eligibility criteria
The study population consists of patients of 18 years
and older with advanced cancer who are admitted to the
PCU. Additional inclusion criteria are the ability to speak
English, a Palliative Performance Scale (PPS) score [57] of
30 % or higher at the time of consent, and cognitive cap-
acity to provide informed consent (or an accessible SDM
who is able to provide consent). Exclusion criteria are: delir-
ium present on admission, as assessed clinically with the
CAM [58]; known psychotic disorder other than dementia;
inability to take medications sublingually or via gastrostomy
tube; known allergy to melatonin or placebo content; use of
melatonin within the 2 weeks preceding admission; patients
on warfarin treatment or other anticoagulant administered
per os, on other investigational agents or treatments or on
immunosuppressant medication in the context of auto-
immune disease or post organ transplantation; communica-
tion problems that cannot be accommodated, including
deafness, tracheostomy, aphasia, dysarthria or emotional
distress; severe visual impairment or being designated le-
gally blind; and pregnancy or lactation.
Assessed for eligibility (n=  )
Excluded  (n=   )
Not meeting inclusion criteria (n=  )
Declined to participate (n=  )
Other reasons (n=  )
Analysed  (n=  )
Excluded from analysis (with reasons) (n=  )
Lost to follow-up (n=  )
Discontinued Placebo (with reasons) (n=  )
Allocated to Placebo po daily (n=  )
Received at least one dose (n=  )
Did not receive even one dose (give 
reasons) (n=  )
Lost to follow-up (with reasons) (n=  )
Discontinued Melatonin (with reasons) (n= )
Allocated to Melatonin 3mg po daily (n=  )
Received at least one dose (n=  )
Did not receive even one dose (give 
reasons) (n=  )
Analysed  (n=  )
Excluded from analysis (with reasons) (n=  )
Allocation
Analysis
Follow-Up
Randomized (n=  )
Enrollment
Fig. 1 Overview of study design for melatonin feasibility study
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Randomization, allocation concealment and blinding
This study aims to minimize selection bias by using
randomization and allocation concealment. Upon con-
firmation of eligibility, the participant will be randomized
in a 1:1 ratio of melatonin to placebo treatment. We will
use an independent web-based randomization system
(Ottawa Hospital Research Institute (OHRI) Data
Management Services) that provides the group allocation
according to a randomization list, pregenerated by an in-
dependent statistician. This central randomization system
ensures allocation concealment. The randomization
master list will be kept confidential and secure by OHRI
Data Management Services, the Director of Pharmacy at
Bruyère Continuing Care and the pharmacy technician
who sets up the prepackaged study (active or placebo)
medication. The confidential participant assignment rec-
ord is held by the Director of Pharmacy. The study inves-
tigators, other research team members, PCU pharmacist,
PCU physicians, PCU nurses, dispensing pharmacist and
technician and other health care personnel will remain
blinded to the study medication, except in the case of ap-
proved emergency unblinding.
Study drug and intervention protocol
The study medication tablets for both melatonin and
placebo appear identical and are prepackaged in small
blue containers labeled according to Natural Health
Products Regulations and Good Labeling Practices. Both
melatonin and matching placebo tablets have been man-
ufactured and obtained from the same pharmaceutical
company. Once prescribed by one of the PCU physi-
cians, the dispensed container is sent to the unit by a
pharmacy technician.
On study day 1 (D1), enrolled patients receive the study
medication consisting of a tablet administered sublingually
or via gastrostomy tube of either 3 mg melatonin (immedi-
ate-release) or placebo at 21:00 h (±1 h) until study day 28
(D28) of informed consent, or earlier in the event of death
or discharge. In the event of incident delirium occurring
before D28, the study drug is discontinued immediately.
As standard practice on our unit, patients are assessed at
the end of each 8-hour nursing shift with the Nursing De-
lirium Screening Scale (Nu-DESC) [59] to observationally
screen for the presence of delirium. The Confusion Assess-
ment Method (CAM) [58] is subsequently performed by a
PCU physician as a confirmatory diagnostic test of delir-
ium if Nu-DESC screening is positive.
Withdrawals and discontinuation
The study medication will be stopped if any of the
following occurs:
 Participant death or discharge
 Incident delirium
 Participant experiences adverse event(s) that require
discontinuation in the judgment of the principal
investigator or designee
 Participant has a need for additional medication that
would interfere with the trial
 The participant neglects to follow trial instructions
 The participant or their legally authorized
representative request consent withdrawal
 The sponsor or the principal investigator or the
Data Safety Monitoring Board (DSMB) or a
government agency, such as Health Canada,
terminates the study
Data collection
Data recorded at admission
Table 1 summarizes the study schedule of enrollment,
interventions and assessments using the SPIRIT tem-
plate [60]. Routine data will be recorded at admission
and include: gender, age, documentation of cancer diagno-
sis and current medication list. Routine assessments at ad-
mission to be recorded include: the PPS [57], the CAM
[58], the Short Orientation-Memory-Concentration Test
(SOMCT) [61], the Edmonton Classification System for
Cancer Pain (ECS-CP) [62] and the Edmonton Symptom
Assessment System-revised (ESAS-r) [63]. These evalua-
tions are routinely conducted on all patients on admission
to the PCU as part of the admission process. Routine
screening with the Nu-DESC [59] starts from the time of
patient admission.
The PPS assesses functional status and measures pro-
gressive decline in palliative care patients. It is routinely
completed within the first 24 h of admission to the
PCU. The CAM is used for delirium screening at admis-
sion and has a diagnostic algorithm. (Nu-DESC ratings
are not available at admission). The SOMCT is a brief,
validated cognitive screening tool. The ECS-CP gener-
ates a complexity profile in relation to the challenge of
achieving stable cancer pain control. The ESAS-r is a
widely used tool to describe symptom intensity for nine
common symptoms (pain, tiredness, drowsiness, nausea,
appetite, shortness of breath, anxiety, depression and
wellbeing) in palliative care, and is based on self-report.
The Nu-DESC is a brief, validated observational screen-
ing tool for delirium that is completed by the patient’s
bedside nurse at the end of each 8-hour nursing shift.
Data recorded during study
Data relating to predisposing factors for delirium will be
collected on study day 1 (D1) by the CRN or CRA using
a standard checklist. The Charlson Co-morbidity Index
(CCI) [64] and Baseline Risk Profile for Delirium in the
Cancer Trajectory (BRP-DICT) (developed ad hoc by the
senior author) will be rated on D1. The CRN or CRA
will visit the PCU daily (on weekdays) to collect data
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on Nu-DESC and ESAS-r scores, CAM results and
concomitant medications and enquire about adverse events
while the participant is enrolled in the trial and up to 48 h
after the trial medication has stopped. The designated goals
of care (GOC), established by consensus following discus-
sions with the patient or SDM, will be recorded on D1 and
at the time of diagnosis of incident delirium. Consistent
with patient and family wishes, the designated goals of care
(ranging in category from full resuscitation to comfort care
only) help to determine the degree of intensity applied to
the investigation and treatment of an episode of delirium.
This approach is consistent with the “Canadian guidelines
on the assessment and treatment of delirium in older
adults at the end of life” [26]. The Insomnia Severity Index
Table 1 Schedule of enrollment, interventions and assessments (using the SPIRIT template [60]) for the melatonin feasibility study
Study period
Enrollment Allocation Post-allocation Close-out
Timepoint At admission Within
72 h of
admission
Day 1 to
Day 28
Day 29
and Day 30
At suspicion
of delirium
Delirium
diagnosis
confirmed
24 (16–32) h
after delirium
diagnosis
Within 3 days
after delirium
diagnosis
30-day period
after stop of
trial product
(D1–D28) (D29 + 30)
Enrollment:
Eligibility screen: verbal
consent to be contacted
by research team member
X
Informed consent X
Allocation X
Interventions:
Administer
melatonin/placebo
X Daily:
@ 21:00
± 1 h
Discontinue
trial product
(trial product
return/count)
Assessments:
Medical history X
GOC X X
PPS X
ECS-CP X
CAM X X
SOMCT X
Nu-DESC X X
ESAS-r X X
Concomitant
medications/NHP
X X
AE data collection X X X X X X X
BRP-DICT X D1 only
CCI X D1 only
ISI X D1, 14,
28 ±
2 days
PCU physician CGR X
MDAS X
PP-DICT X
Contact HCP for
SAE outcome/death
X
Abbreviations: AE/SAE adverse event/serious adverse event, BRP-DICT Baseline Risk Profile for Delirium in the Cancer Trajectory, CAM Confusion Assessment
Method, CCI Charlson Co-morbidity Index, CGR Clinical Global Rating Scale, ESAS-r Edmonton Symptom Assessment System-revised, GOC goals of care, HCP health
care professional, ISI Insomnia Severity Index, MDAS Memorial Delirium Assessment Scale, NHP Natural Health Product, Nu-DESC Nursing Delirium Screening Scale,
PCU palliative care unit, PP-DICT Precipitant Profile for Delirium in the Cancer Trajectory, PPS Palliative Performance Scale, SOMCT Short Orientation Memory
Concentration Test
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(ISI) [65] is a short, subjective and validated tool that
measures a patient’s self-reported views about his or
her insomnia. This instrument will be rated by the pa-
tient on D1, and once in each of the time ranges D14 ±
2 d and D28 ± 2 d. The Memorial Delirium Assessment
Scale (MDAS) [66] is a validated delirium-severity rat-
ing tool that also captures psychomotor and sleep-wake
cycle disturbance. The MDAS will be rated by the CRN
on weekdays in all incident cases of delirium encom-
passing the first 24 h of delirium. (It is not possible as
part of this feasibility study to rate the MDAS on the
weekends due to limited resources). The PCU attending
physician will be independently asked to provide a
Clinician Global Rating (CGR) of delirium severity at the
time of delirium diagnosis. This rating has three categor-
ies: mild, moderate and severe. In addition, precipitating
factors at the time of incident delirium will be collected by
the CRN or CRA using a standard checklist (Precipitant
Profile for Delirium in the Cancer Trajectory (PP-DICT))
developed ad hoc by the senior author. Table 1 summa-
rizes the study schedule of enrollment, interventions
and assessments.
Data and Safety Monitoring
Adverse events will be graded by the investigator using
the National Cancer Institute’s “Common terminology
criteria for adverse events (NCI-CTCAE v 4.03)” [67].
Information about all adverse events, whether volunteered
by the study participant, discovered by the investigator or
designee’s questioning, laboratory test or other means, will
be recorded and followed as appropriate. The Data and
Safety Monitoring Board (DSMB) for this study will com-
prise one statistician methodologist, one palliative care
specialist, and one individual knowledgeable in Natural
Health Products for conduct monitoring and supervision
of the clinical trial. The DSMB will meet at least once
before the study starts and then meet according to the
DSMB terms of reference. After every 20th enrolled pa-
tient, a trial monitor, who is not part of the research
team, will review the trial documentation to ensure that
the trial is being conducted according to the trial proto-
col, the International Conference on Harmonization
Good Clinical Practice (ICH GCP), and regulatory
requirements.
Data analysis plan
This feasibility study is not powered to test efficacy.
However, we anticipate that it will generate useful data
regarding recruitment and retention rates, protocol vio-
lation frequency, and some preliminary data on time to
onset of first episode of incident delirium during their
inpatient admission. These data will further assist in the
estimation of sample size for the larger study, as well as
its projected duration and cost. Data will be reported
regarding the acceptability of the study procedures to
patients, families and palliative care unit staff, including
pharmacy. The effectiveness of the blinding process will
be assessed. Collectively, these outcome data will ultim-
ately determine the feasibility of the larger trial. Although
the statistical analysis in this feasibility study will be
mainly descriptive, we will also assess time to first episode
of incident delirium with a Kaplan-Meier survival analysis.
The upper one-sided 95 % limit of median time to onset
will also be derived to further guide sample size consider-
ations for the full randomized trial.
Discussion
We have chosen to limit the study participants to those
with a cancer diagnosis, as a heterogeneous study sam-
ple with a variety of life-threatening illnesses could con-
ceivably make it more difficult to achieve a good balance
in the two study arms and thus lead to confounding.
Our study will include patients with dementia, which is
one of the strongest predisposing risk factor for the devel-
opment of delirium, along with advanced age. Although
this will generate some challenges in the assessment of de-
lirium superimposed on dementia, we postulate that those
with dementia may well be the group that is most likely to
benefit from melatonin.
We have chosen to implement the “Canadian guide-
lines on the assessment and treatment of delirium in
older adults at the end of life” [26] as part of this feasi-
bility study. We do not anticipate that this will interfere
with any data analysis, as the implementation of these
guidelines will be consistent for all randomized study pa-
tients and all inpatients on the PCU. As part of our feasi-
bility study, we are piloting standardized checklists that
were designed to comprehensively and systematically cap-
ture data regarding predisposing risk factors for delirium at
admission (through the BRP-DICT form) and precipitating
factors for delirium in the 24 h post delirium diagnosis
(through the PP-DICT form).
The research nurse and research assistant are docu-
menting field notes during this study, thus adding a quali-
tative component to this study. These “lessons learned”
will provide additional insights into the potential barriers
and feasibility of subsequent studies. The outcomes of this
feasibility study will provide information on recruitment
and retention rates, protocol violation frequency, effective-
ness of the blinding process, acceptability of the study pro-
cedures and safety of the proposed intervention. This will
inform the design of a fully powered RCT to evaluate the
preventative role of melatonin administration in patients
with advanced cancer.
Trial status
The trial is currently recruiting patients.
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Additional file
Additional file 1: SPIRIT checklist for melatonin feasibility study.
Populated SPIRIT checklist (Page numbers refer to location in manuscript).
(PDF 85 kb)
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